Company Profile
Business Scope
A pharmaceutical scope spanning research and development, manufacturing and regional markets.
Company Profile
Our scope in numbers
products are exported
registered products
products registered in the Kingdom of Saudi Arabia
employees
Company Profile
Description of the Principal Activities of the Company and Its Subsidiaries
Avalon Pharma was established in 1998 in Riyadh as a Saudi joint-stock company, operating in the development, manufacturing, and marketing of generic medicines and pharmaceutical products, including prescription drugs. During the financial year ending 2025, the Company continued its activities in accordance with its articles of association and in compliance with relevant laws and regulations, including the Capital Market Authority regulations applicable to listed companies.
During 2025, the Company continued to develop its operational processes based on scientific research, specialized studies, and continuous monitoring of the latest developments in the pharmaceutical industry at both the local and global levels.
01
First: Products and Markets
Avalon Pharma owns a product portfolio of more than 275 products distributed across over 80 brands, covering several therapeutic categories, the most prominent of which are:
The Company’s products are marketed within the Kingdom of Saudi Arabia, with a phased expansion into regional markets in accordance with the approved strategic plans.
- 01Dermatological Diseases
- 02Respiratory Diseases
- 03Neurological Diseases
- 04Musculoskeletal Diseases
- 05Urinary System Diseases
02
Second: Research and Development
The Company places great importance on research and development activities, considering them a key element in achieving sustainable growth. During 2025, Avalon Pharma continued investing in its advanced Research and Development Center, which operates according to the highest approved technical standards and includes a qualified team of scientists, researchers, and experts. The center contributes to the development of new products, the improvement of existing products, and ensuring compliance with quality requirements and relevant regulations.
03
Third: Future Outlook
The Company aims, in the coming periods, to continue its operational growth and improve performance efficiency, with a focus on:
- 01
Strategic Expansion of the Product Portfolio.
- 02
Enhancing Investment in Research and Development.
- 03
Full Compliance with Regulations and Instructions Issued by Relevant Regulatory Authorities.
While emphasizing that any forward-looking expectations are subject to a number of risks and challenges that may affect the actual results.